11
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T79314 | PD-L1-IN-3 | PD-1/PD-L1 | |
PD-L1-IN-3 (Compound 4a) functions as an inhibitor targeting the PD-1/PD-L1 axis, with an IC50 value of 4.97nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1/PD-L1... | |||
TP1463 | PD-1/PD-L1-IN 3 TFA (1629654-95-0 free base) | PD-1/PD-L1-IN 3 TFA | |
PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM. | |||
T73642 | PD-1/PD-L1-IN 3 TFA | ||
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, serves as a potent and selective inhibitor of PD-1/PD-L1 interaction. This compound disrupts PD-L1's binding with PD-1 and CD80 by directly binding to PD-L1, exhibiting IC50 va... | |||
T79740 | CYP51/PD-L1-IN-3 | ||
CYP51/PD-L1-IN-3 (compound L21), a quinazoline with antifungal properties, serves as a dual inhibitor targeting CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM). This compound promotes early fungal apoptosis within the ... | |||
T37535 | Camrelizumab | SHR-1210 | |
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up to 3 nM and is inhibitory to PD-1/PD-L1 with an IC50 of 0.7... | |||
T6S0071 | Fraxinellone | HIF/HIF Prolyl-Hydroxylase , STAT , PD-1/PD-L1 | |
1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhibited a variety of insecticidal activities including feeding... | |||
T72691 | PD-1/PD-L1-IN-28 | ||
PD-1/PD-L1-IN-28, an inhibitor of the PD-1/PD-L1 signaling pathway (IC 50 = 0.744 µM), demonstrates promising research potential in tumor immunity. This immune checkpoint inhibitor effectively blocks the interaction with... | |||
T79634 | LYP-IN-3 | Phosphatase | |
LYP-IN-3 (compound D34) is a selective Lymphoid-tyrosine phosphatase (LYP) inhibitor (Ki=0.93 μM) that modulates the T-cell receptor (TCR) signaling pathway during tumor progression. It promotes T-cell activation, hinder... | |||
T36047 | LH1307 | ||
LH1307 is an inhibitor of the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 that has an IC50 value of 3 nM in a homologous time-resolved fluorescence (HTRF) assay.1 It increases the activation o... | |||
T82414 | Favezelimab | MK-4280 | |
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that inhibits the LAG-3/MHC class II interaction and shows potential for use in colorectal cancer (CRC) research, particularly when combined with the PD... | |||
T76997 | Socazolimab | ||
Socazolimab (ZKAB001), an anti-PD-L1 monoclonal antibody, demonstrates enduring safety and efficacy in treating recurrent or metastatic cervical cancer. Additionally, it shows promise for treating small cell lung cancer,... |